Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20463693 | 0.83 | L3MBTL1 (0.44) | KDM4ERAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL842107 | 0.82 | MAPT (0.50) | KDM4ERAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL29521181 | 0.82 | MAPT (0.50) | KDM4ERAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL20456075 | 0.82 | HTT (0.36) | KDM4EKMT2ALMNAHPGDALDH1A1 | |
| SCHEMBL25371933 | 0.81 | EPHX2 (0.43) | KDM4EEPHX2HPGDIDO1SLC6A4 | |
| SCHEMBL30694809 | 0.81 | EPHX2 (0.43) | KDM4EEPHX2HPGDIDO1SLC6A4 | |
| SCHEMBL89647 | 0.80 | S1PR4 (0.41) | KDM4ERAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL29098918 | 0.80 | SMN1; SMN2 (0.45) | KDM4ERAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL17893778 | 0.79 | L3MBTL1 (0.53) | KDM4ERAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL4640186 | 0.79 | KDM4E (0.40) | KDM4ERAB9AKMT2ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3577118-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-10442804-B2 | Compounds for the treatment of hepatitis B virus infection | GILEAD SCIENCES, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180251460-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2018-09-06 | — | — | US | disclosed |
| WO-2018144605-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144605-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| EP-1958666-A1 | Heterocyclic-substituted alkanamides as therapeutic compounds | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | NOVARTIS AG (CH) | 2008-07-24 | — | — | US | disclosed |
| EP-1856032-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006095020-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251460-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | HAVCR2, PYGL, OAT | KDM4E 4217/4885RAB9A 3145/4885KMT2A 4477/4885 |
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | REN, ACE, AGTR1 | KDM4E 1612/4885RAB9A 646/4885KMT2A 2552/4885 |
| US-10442804-B2 | Compounds for the treatment of hepatitis B virus infection | HAVCR2, PYGL, OAT | KDM4E 4217/4885RAB9A 3145/4885KMT2A 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.